 Celularity Inc has closed the merger with GX Acquisition Corp NASDAQ: GXGX, giving Celularity 138 million to push the NK cell and T cell therapies into early-stage trials. The combined company will operate under the name Celularity Inc NASDAQ: CELU, and its common stock will commence trading on the NASDAQ from Monday 19 July under the ticker symbol CELU. 